EBC - Discussions

ENG

Keynote 522, OPTIMA

ASCO 2026

Who gets What - selecting the right treamtent for the…

D. Lüftner, MD, A. Schneeweiss, MD, E. de Azambuja, MD, PhD, E. Senkus-Konefka

EBC - 100 seconds

ENG

lidera BC

ASCO 2026

Adjuvant girestrant is effective regardless of…

Andreas Schneeweiss, MD

ENG

OPTIMA

ASCO 2026

Optimizing strategies for high and low genomic risk in…

Shani Paluch-Shimon, MD

ENG

lidERA BC

ASCO 2026

Giredestrant in the adjuvant setting

Peter A. Fasching, MD

ENG

OPTIMA

ASCO 2026

First results of PAM50 assay as deescalation…

Eva M. Ciruelos, MD, PhD

ENG

lidERA BC

ASCO 2026

Oral SERDs are entering the adjuvant setting

Wolfgang Janni, MD

ENG

NATALEE

ASCO 2026

The genomic analysis of patients treated in natalee…

Eva M. Ciruelos, MD, PhD

ENG

ASCO 2026

Optimal chemo approach in HR+ / HER2– early breast…

Nadia Harbeck, MD, PhD

ENG

KEYNOTE-522

ASCO 2026

Outstanding improvement with pembrolizumab in early…

Javier Cortés, MD, PhD

ENG

PREPEC

ASCO 2026

Pre vs. sub: Where should the implant go?

Wolfgang Janni, MD

ENG

OPTIMA

ASCO 2026

Moving forward with genomic-based deescalation

Elzbieta Senkus-Konefka, MD, PhD

ENG

NATALEE

ASCO 2026

Presentation of extensive translational data

Peter A. Fasching, MD

ENG

lidERA BC

ASCO 2026

New promising endocrine therapies arising in pre- and…

Shani Paluch-Shimon, MD

EBC – 100 seconds multi language

ISR

lidERA BC

ASCO 2026

"טיפולים אנדוקריניים חדשניים ומבטיחים בנשים עם סרטן שד…

Shani Paluch-Shimon, MD

ESP

OPTIMA

ASCO 2026

Primeros resultados del ensayo PAM50 para la…

Eva M. Ciruelos, MD, PhD

POL

OPTIMA

ASCO 2026

Kolejny krok ku deeskalacji leczenia na podstawie badań…

Elzbieta Senkus-Konefka, MD, PhD

ESP

NATALEE

ASCO 2026

Análisis genómico de las pacientes tratadas en el…

Eva M. Ciruelos, MD, PhD

ISR

OPTIMA

ASCO 2026

אופטימיזציה של אסטרטגיות טיפול עבור מטופלות עם סיכון…

Shani Paluch-Shimon, MD

ESP

KEYNOTE-522

ASCO 2026

Mejora sobresaliente con pembrolizumab en el cáncer de…

Javier Cortés, MD, PhD

ABC - Discussions

ENG

Destiny-Breast09, HER2Climb-05

ASCO 2026

New chances for patients

V. Müller, MD, N. Harbeck, MD, PhD, V. Guarneri, MD, PhD, B. Pistilli, MD, A. Gennari, MD, PhD

ENG

ASCENT-03, ASCENT-04, Future 2.0, PALMARES-2, AMBITION

ASCO 2026

Redefining systemic therapy

D. Lüftner, MD, A. Schneeweiss, MD, E. de Azambuja, MD, PhD, E. Senkus-Konefka

ENG

SAKK 96/12 REDUSE, evERA, persevERA, SERENA 6

ASCO 2026

Practice changing data and oral SERDs combinations

V. Müller, MD, N. Harbeck, MD, PhD, V. Guarneri, MD, PhD, B. Pistilli, MD, A. Gennari, MD, PhD

ABC – 100 seconds

ENG

ASCENT-04

ASCO 2026

Biomarker analysis

Barbara Pistilli, MD

ENG

ASCENT-04

ASCO 2026

Biomarker analysis of ASCENT-04

Evandro de Azambuja, MD, PhD

ENG

ASCENT-03, ASCENT-04

ASCO 2026

Biomarkers for patient selection – ASCENT-04 + 03

Andreas Schneeweiss, MD

ENG

REDUSE

ASCO 2026

Denosumab every 3 months is also effective

Nadia Harbeck, MD, PhD

ENG

SERENA-6

ASCO 2026

Optimizing cancer therapy using liquid biopsy

Wolfgang Janni, MD

ENG

PALMARES-2

ASCO 2026

Treatment beyond progression in the setting of…

Diana Lüftner, MD

ENG

DESTINY-Breast09

ASCO 2026

Subanalysis of DB-09 trial for complete and deep…

Eva M. Ciruelos, MD, PhD

ENG

ASCENT-04, ASCENT-03

ASCO 2026

SG is effective across all subgroups

Diana Lüftner, MD

ENG

FUTURE 2.0

ASCO 2026

Can the treatment of metastatic TNBC be individualized…

Elzbieta Senkus-Konefka, MD, PhD

ENG

PALMARES-2

ASCO 2026

Real-world data support the use of local therapies in…

Andreas Schneeweiss, MD

ENG

Future 2.0

ASCO 2026

A biomarker-driven therapy in pretreated TNBC shows…

Andreas Schneeweiss, MD

ENG

DESTINY-Breast09

ASCO 2026

Better response correlates with longer PFS

Andreas Schneeweiss, MD

ENG

PANKU-Breast02

ASCO 2026

Iza-bren in metastatic TNBC

Valentina Guarneri, MD, PhD

ENG

SAKK 96/12 REDUSE

ASCO 2026

Non-inferiority of denosumab q12w

Valentina Guarneri, MD, PhD

ABC – 100 seconds multi language

ESP

DESTINY-Breast09

ASCO 2026

Subanálisis del ensayo DB-09: la respuesta completa y…

Eva M. Ciruelos, MD, PhD

FRA

ASCENT-04

ASCO 2026

Analyse des biomarqueurs

Barbara Pistilli, MD

POL

FUTURE 2.0

ASCO 2026

Czy leczenie zaawansowanego raka trójujemnego może być…

Elzbieta Senkus-Konefka, MD, PhD

ITA

ASCENT-04

ASCO 2026

Analisi dei biomarcatori

Barbara Pistilli, MD

ITA

PANKU-Breast02

ASCO 2026

Iza-bren nel carcinoma mammario triplo negativo…

Valentina Guarneri, MD, PhD

ITA

SAKK 96/12 REDUSE

ASCO 2026

Non-inferiorità di denosumab q12w

Valentina Guarneri, MD, PhD

Poster Insights - 100 seconds

ENG

ZN-A-1041-101-US

ASCO 2026

ZN-A-1041 in HER2+ Metastatic Breast Cancer

Nancy U. Lin, MD, Volkmar Müller, MD

Gynecologic Cancer - 100 seconds

ENG

NRG-GY018

ASCO 2026

Updated overall survival and subsequent therapies in…

Diana Lüftner, MD

ENG

RUBY

ASCO 2026

RUBY: A curative intent in FIGO stage III / IV?

Diana Lüftner, MD

ENG

ASCO 2026

Nectin-4 targeting ADC CRB-701 shows promising activity…

Yohann Loriot, MD, PhD

Gynecologic Cancer - 100 seconds multi language

FRA

ASCO 2026

Le conjugué anticorps-médicament ciblant Nectin-4,…

Yohann Loriot, MD, PhD

NSCLC advanced / metastatic - 100 seconds

ENG

CROWN

ASCO 2026

CROWN: 7-year data confirm lorlatinib as SOC in ALK-pos…

Nicolas Girard, MD

ENG

WU-KONG28

ASCO 2026

EGFR exon20ins: Sunvozertinib in 1L

Frank Griesinger, MD, PhD

ENG

CROWN

ASCO 2026

Lorlatinib is becoming a better treatment option for…

Denis Moro-Sibilot, MD

ENG

CHRYSALIS-2, WU-KONG28, LIBRETTO-432, HARMONi-6, CROWN, LORIN

ASCO 2026

ASCO 2026: a recap on lung cancer

Alfredo Addeo, MD

ENG

HARMONi-6

ASCO 2026

HARMONi-6: Ivonescimab + chemo demonstrates superior OS…

Lizza Hendriks, MD, PhD

ENG

ASCO 2026

Delayed brain radiation therapy in the era of TKI with…

Riyaz Shah, MD

ENG

CHRYSALIS-2

ASCO 2026

Novel approaches for atypical EGFR-mutated NSCLC

Nicolas Girard, MD

ENG

HARMONi-6

ASCO 2026

Ivonescimab: a great comback of anti-androgenic agents…

Denis Moro-Sibilot, MD

ENG

WU-KONG28

ASCO 2026

exon20ins: a small molecular subgroup with new…

Michael Thomas, MD

ENG

ASCO 2026

PF-08634404: a novel biscpec PD-1/VEGF antibody

Martin Reck, MD

ENG

CHRYSALIS-2

ASCO 2026

uncommon EGFRm – robust data for amivantamab and…

Michael Thomas, MD

ENG

CROWN

ASCO 2026

Lorlatinib: SOC in ALK-pos NSCLC

Frank Griesinger, MD, PhD

ENG

ROSETTA Lung-02

ASCO 2026

VEGF-inhibition revisited

Hossein Borghaei, MD

ENG

HARMONi-6

ASCO 2026

Ivonescimab as first-line therapy in squamous NSCLC

Frank Griesinger, MD, PhD

ENG

CROWN

ASCO 2026

7 yrs of f/u of CROWN shows sustained disease control…

Lizza Hendriks, MD, PhD

ENG

Krascendo-170

ASCO 2026

New treatment options for 1L therapy of KRAS…

Noemi Reguart, MD

ENG

CHRYSALIS-2

ASCO 2026

Uncommon EGFRm NSCLC – firstline therapy

Frank Griesinger, MD, PhD

ENG

HARMONi-6

ASCO 2026

A positive take on a positive trial

Stephen Liu, MD

ENG

HARMONi-6

ASCO 2026

HARMONi-6: analysis of OS data

Martin Reck, MD

ENG

WU-KONG28

ASCO 2026

TKIs entering exon20 insertion space

Riyaz Shah, MD

ENG

CROWN

ASCO 2026

CROWN keeps running

Michael Thomas, MD

ENG

HARMONi-6

ASCO 2026

Bispecific antibodies with VEGF-component increasingly…

Michael Thomas, MD

ENG

OptiTROP-Lung05

ASCO 2026

OptiTROP-Lung05: sac-TMT + pembro vs. pembro as 1L…

Nicolas Girard, MD

ENG

ARCHER

ASCO 2026

Abrogating acquired resistance in ALK+ disease with a…

Riyaz Shah, MD

ENG

OptiTROP-Lung05

ASCO 2026

OptiTROP-Lung05 – another building block in the overall…

Michael Thomas, MD

ENG

ROSETTA Lung-02

ASCO 2026

New bispecs for NSCLC

Stephen Liu, MD

ENG

ASCO 2026

Radiation therapy timing for driver mutated NSCLC

Frank Griesinger, MD, PhD

NSCLC advanced / metastatic - 100 seconds multi language

FRA

HARMONi-6

ASCO 2026

Ivonescimab: le grand retour des agents…

Denis Moro-Sibilot, MD

NED

CROWN

ASCO 2026

7y follow-up van CROWN laat duurzame ziektecontrole…

Lizza Hendriks, MD, PhD

NED

HARMONi-6

ASCO 2026

HARMONI-6: ivonescimab + chemo laat betere overleving…

Lizza Hendriks, MD, PhD

ESP

Krascendo-170

ASCO 2026

Nuevas opciones terapéuticas para el tratamiento de…

Noemi Reguart, MD

FRA

OptiTROP-Lung05

ASCO 206

OptiTROP-Lung05: Sac-TMT et immunothérapie en premiere…

Nicolas Girard, MD

FRA

CHRYSALIS-2

ASCO 2026

Nouvelles stratégies dans les CBNPC EGFR mutés

Nicolas Girard, MD

FRA

CROWN

ASCO 2026

Données à 7 ans de l’essai CROWN: le lorlatinib,…

Nicolas Girard, MD

FRA

CROWN

ASCO 2026

Le lorlatinib s'impose comme une meilleure option…

Denis Moro-Sibilot, MD

NSCLC early stages - 100 seconds

ENG

AEGEAN

ASCO 2026

AEGEAN: Characaterization of the tumor microenviromet

Martin Reck, MD

ENG

LIBRETTO-432

ASCO 2026

Molecular testing extends into the perioperative…

Michael Thomas, MD

ENG

LIBRETTO-432

ASCO 2026

Improved EFS with adjuvant selpercatinib in RET+ NSCLC

Lizza Hendriks, MD, PhD

ENG

LORIN

ASCO 2026

Neoadjuvant approach for ALK+ NSCLC

Sacha Rothschild, MD, PhD

ENG

CHRYSALIS-2, WU-KONG28, LIBRETTO-432, HARMONi-6, CROWN, LORIN

ASCO 2026

ASCO 2026: a recap on lung cancer

Alfredo Addeo, MD

ENG

LIBRETTO-432

ASCO 2026

Selpercatinib in the adjuvant setting for RET-positive…

Frank Griesinger, MD, PhD

ENG

LIBRETTO-432

ASCO 2026

Selpercatinib: a new targeted therapy for operated…

Denis Moro-Sibilot, MD

NSCLC early stages - 100 seconds multi language

NED

LIBRETTO-432

ASCO 2026

Verbeterde event vrije overleving met adjuvant…

Lizza Hendriks, MD, PhD

FRA

LIBRETTO-432

ASCO 2026

Selpercatinib: un nouveau traitement ciblé destiné aux…

Denis Moro-Sibilot, MD

SCLC - 100 seconds

ENG

DeLLphi-304

ASCO 2026

ASCO 2026: New Advances in SCLC

Sacha Rothschild, MD, PhD

ENG

ASCO 2026

The future treatment of advanced SCLC

Noemi Reguart, MD

ENG

ASCO 2026

Developing new strategies for SCLC

Stephen Liu, MD

ENG

ASCO 2026

Nuances for tarlatamab use in SCLC

Riyaz Shah, MD

SCLC - 100 seconds multi language

ESP

ASCO 2026

Tratamiento futuro del cáncer de pulmón microcítico…

Noemi Reguart, MD

Discussions

ENG

PLUDO

ASCO 2026

Chemo vs. radioligands: how to select the right therapy…

M. Grimm, MD, A. Bjartell, MD, PhD, L. Krabbe, MD, V. Grünwald, MD

ENG

Proteus

ASCO 2026

Practice changing or practice informing data?

N. Shore, MD, A. S. Meresburger, MD, M. Grimm, MD, S. Chowdhury, PhD, D. Murphy, MD, A. Bjartell, MD, PhD

ENG

TALAPRO-3, ZZFIRST

ASCO 2026

Test Early, Treat Smarter

A. S. Meresburger, MD, M. Grimm, MD, S. Chowdhury, PhD, A. Bjartell, MD, PhD, V. Grünwald, MD

Prostate cancer - 100 seconds

ENG

TALAPRO-3

ASCO 2026

HRR testing - now mandatory!!

Philipp Ivanyi, MD

ENG

PROTEUS

ASCO 2026

Perioperative ADT + ARPI for high risk prostate cancer

Eleni Efstathiou, MD, PhD

ENG

TALAPRO-3

ASCO 2026

TALAPRO-3 has demonstrated level 1 evidence for a new…

Neal Shore, MD

ENG

ARACOG

ASCO 2026

Cognitive Impairment With Enzalutamide

Peter Goebell, MD

ENG

COMPPARE

ASCO 2026

Proton or Photon Therapy

Axel S. Merseburger, MD

ENG

PROTEUS

ASCO 2026

PROTEUS changes perioperative management for high risk…

Neal Shore, MD

ENG

TALAPRO-3

ASCO 2026

Next kid on the block

Peter Goebell, MD

ENG

PROTEUS

ASCO 2026

Apalutamide becomes the new standard of care in the…

Diana Lüftner, MD

ENG

TALAPRO-3

ASCO 2026

PARP-inhibition in mCSPC

Eleni Efstathiou, MD, PhD

ENG

PROTEUS

ASCO 2026

PROTEUS changes Prostate Cancer

Declan Murphy, MD

ENG

Proteus

ASCO 2026

Practice-changing: Hit hard and early

Philipp Ivanyi, MD

ENG

PROTEUS

ASCO 2026

Therapy Optimization Around Prostatectomy

Axel S. Merseburger, MD

Prostate cancer - 100 seconds multi language

GRE

PROTEUS

ASCO 2026

Περιεγχειρητική ADT + ARPI για καρκίνο του προστάτη…

Eleni Efstathiou, MD, PhD

GRE

TALAPRO-3

ASCO 2026

Αναστολή του PARP σε mCSPC

Eleni Efstathiou, MD, PhD

Discussions

ENG

KEYNOTE-564, RAMPART

ASCO 2026

News from the adjuvant kidney cancer space

P. Goebell, P. Ivanyi, H. Hammers, T. Powles, B. Rini

ENG

ASCO 2026

New targets

P. Goebell, P. Ivanyi, H. Hammers, B. Rini, V. Grünwald

Kidney cancer - 100 seconds

ENG

ASCO 2026

Microbiome modulation before systemic therapy in mRCC

Peter Goebell, MD

ENG

KEYNOTE-564

ASCO 2026

Do Biomarkers Help?

Peter Goebell, MD

ENG

ASCO 2026

New bispecific antibody in nccRCC: Cadonilimab

Peter Goebell, MD

ENG

ASCO 2026

Patient view of toxicity

Brian Rini, MD

RADICAL

ASCO 2026

Cabozantinb is active in bone metstatic RCC

Viktor Grünwald, MD

ASCO 2026

When bacteria helps to induce responses

Viktor Grünwald, MD

ENG

RAMPART

ASCO 2026

What is the role of adjuvant CTLA4-inhibition in RCC

Brian Rini, MD

ASCO 2026

Breakthrough in medullary renal cell carcinoma?

Viktor Grünwald, MD

Discussions

ENG

SAKK 06/19

ASCO 2026

Bladder sparing - where are we and what is the future?

L. Krabbe, V. Grünwald, T. Powles, M.-O. Grimm

ENG

AMABASSADOR, POTOMAC, DISCUS

ASCO 2026

Do we need to change QoL-analysis?

L. Krabbe, V. Grünwald, T. Powles

ENG

EV-302, EXCEED, NEXUS-01

ASCO 2026

Can we sequence and/or combine ADCs?

V. Grünwald, T. Powles, M.-O. Grimm

Bladder cancer - 100 seconds

ENG

EV-302

ASCO 2026

EVP remains the gold standard after 3.5 years

Axel S. Merseburger, MD

SAKK 06/19

ASCO 2026

Back to the roots: Next-level immunotherapy for bladder…

Viktor Grünwald, MD

ENG

AMBASSADOR

ASCO 2026

AMBASSADOR: Adjuvant Pembrolizumab

Axel S. Merseburger, MD

ENG

EV-302

ASCO 2026

Less Is Not Yet More

Peter Goebell, MD

ENG

POTOMAC, EV302

ASCO 2026

Exciting data for Bladder Cancer

Petros Grivas, MD, PhD

ENG

NEXUS-01

ASCO 2026

New Options After EV–Pembrolizumab

Peter Goebell, MD

ENG

ASCO 2026

GemFLP for the treatment of metastatic or unresectable…

Peter Goebell, MD

ENG

POTOMAC

ASCO 2026

POTOMAC is approved by the FDA

Neal Shore, MD

ENG

IMvigor011

ASCO 2026

Patient-reported outcomes in IMvigor11

Joaquim Bellmunt, MD, PhD

ENG

Duravelo-2

ASCO 2026

Duravelo-2: Encouraging results for zelenectide…

Yohann Loriot, MD, PhD

Bladder cancer - 100 seconds multi language

GRE

POTOMAC, EV302

ASCO 2026

Συναρπαστικά δεδομένα για τον καρκίνο της ουροδόχου…

Petros Grivas, MD, PhD

ESP

IMvigor011

ASCO 2026

Resultados comunicados por los pacientes en el estudio…

Joaquim Bellmunt, MD, PhD

FRA

Duravelo-2

ASCO 2026

Duravelo-2 : Résultats encourageants pour le…

Yohann Loriot, MD, PhD

Varia - 100 seconds

ENG

ASCO 2026

Beyond the Science

Peter Goebell, MD

ENG

SARC041, PEAK

ASCO 2026

Practice changer Sarcoma

Philipp Ivanyi, MD

ENG

SARC041

ASCO 2026

Abemaciclib as a new standard in metastatic liposarcoma

Diana Lüftner, MD